Elevance Health sets October 21 results: stock trades at EUR 381.50

Published on 10/16/2026 at 09:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 49.83 billion, up 0.80 percent year over year. Elevance Health stock costs EUR 381.50 on October 16, 2026.

Results date and operating figures

Elevance Health set its third-quarter results date for October 21, 2026.
Second-quarter revenue reached USD 49.83 billion, up 0.80 percent year over year.
Elevance Health stock traded at EUR 381.50 at 8:59 a.m. CEST at Lang & Schwarz on October 16, 2026.

Draufsicht-Arrangement mit Aktienzertifikat, ISIN-Karte US2855211023 und Stethoskop — Elevance Health US2855211023 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und medizinischen Utensilien auf Marmor, Illustration mit AI erstellt.

Elevance Health stock (ISIN US0367521038) was trading at EUR 381.50 at Lang & Schwarz on October 16, 2026 at 8:59 a.m. CEST. The company will release its third-quarter 2026 results on October 21, 2026, according to Elevance Health.

October 21 results set the agenda

The scheduled release is the clearest near-term company date. Elevance Health said on October 5, 2026 that results would be published at 6:00 a.m. EDT, followed by a management conference call at 8:30 a.m. EDT.

The upcoming report will test whether the insurer can stabilize earnings after its second-quarter performance. The company serves approximately 104 million consumers, a scale disclosed in the October 5 release, while its business spans medical, pharmacy, behavioral and clinical care solutions.

What does second-quarter revenue mean?

Second-quarter operating revenue was USD 49.83 billion, up 0.80 percent from USD 49.44 billion in the prior-year quarter, while diluted earnings per share reached USD 7.45 against consensus of USD 6.21, according to MarketBeat. The revenue increase was modest, but the earnings comparison was more favorable, making benefit costs and Medicaid performance important parts of the next update.

On October 9, 2026, Cantor Fitzgerald maintained an Overweight rating and a USD 450.00 price target, citing Medicare concerns and the 2027 Medicare Stars ratings, as reported by Investing.com. That view puts the October 21 report at the center of the near-term valuation debate.

Three dates frame the stock

On October 5, 2026, Elevance Health scheduled its third-quarter release for October 21, 2026. On July 15, 2026, the company reported USD 49.83 billion in second-quarter revenue and USD 7.45 diluted earnings per share. On October 9, 2026, Cantor Fitzgerald kept its USD 450.00 target and Overweight rating.

Next reporting milestones

The next two scheduled milestones are the October 21, 2026 results release at 6:00 a.m. EDT and the 8:30 a.m. EDT management conference call. Both events are covered by the company's October 5 release.

Stock price before the results

At Lang & Schwarz, Elevance Health stock was trading at EUR 381.50 on October 16, 2026 at 8:59 a.m. CEST. The pre-market level gives investors a dated euro reference before the company publishes its next quarterly figures.

The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.